Fig. 3. Prophylactic and therapeutic effects of human H7N9 mAbs in mice i.n. challenged with 10 LD₅₀ of A/Anhui/1/2013 H7N9.

a Female mice were i.p. injected 100 μg (equivalent of 5 mg/kg) or 20 μg (equivalent of 1 mg/kg) of the indicated mAbs (as human IgG1 unless otherwise specified) one day before viral challenge; % survival (<20% weight loss) and % body weight of survived mice were plotted over time. b Female mice were i.p. injected 100 μg of the indicated mAbs one day after viral challenge; % survival and % body weight of survived mice were plotted over time. Arrows indicate the time when mAbs were administered. Control groups of a non-H7 placebo mAb and PBS were included. Data for each group were combined from 1 to 2 experiments and shown as mean ‒ SEM. Source data with P values from two-sided unpaired student’s t-test are provided in the Source Data file. Asterisk symbols denote P < 0.05, and # denote P < 0.1.